Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. (Q45916835)

17 December 2017

title

Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. (English)

1 reference

17 December 2017

author name string

J X Zhou

1

1 reference

17 December 2017

H Yang

2

1 reference

17 December 2017

Q Deng

3

1 reference

17 December 2017

X Gu

4

1 reference

17 December 2017

P He

5

1 reference

17 December 2017

Y Lin

6

1 reference

17 December 2017

M Zhao

7

1 reference

17 December 2017

J Jiang

8

1 reference

17 December 2017

H Chen

9

1 reference

17 December 2017

Y Lin

10

1 reference

17 December 2017

W Yin

11

1 reference

17 December 2017

L Mo

12

1 reference

17 December 2017

J He

13

1 reference

17 December 2017

publication date

30 December 2012

1 reference

17 December 2017

published in

Annals of Oncology

1 reference

17 December 2017

volume

24

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

1319-1325

1 reference

17 December 2017

A translational view of the molecular pathogenesis of lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

EML4-ALK fusion gene in Korean non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

PIK3CA mutations and copy number gains in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS626

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS626

1 reference

17 December 2017

PubMed ID

23277484

1 reference

17 December 2017